Right now, classic psychedelics like psilocybin and LSD sit in Schedule I — the US government's most restricted drug category, meaning they're treated as having no medical use. Moving them to a less restricted category requires the DEA (the Drug Enforcement Administration, which controls which drugs are legal) to act, and the DEA only does that after the FDA (the US drug regulator) approves a drug for medical use. Since no FDA approval is coming soon, the legal status of these substances won't change before June 2027. This matters because Schedule I status is what makes research hard, keeps therapists from legally offering these treatments, and blocks insurance coverage.
Schedule I status holds absent FDA approval, which is not coming in this window. The empty DEA docket and absence of any FDA-completed approval that would trigger DEA scheduling review make near-term rescheduling implausible. Falsifiable by any DEA final or interim rule rescheduling a named classic psychedelic.